share_log

Biodexa Pharmaceuticals | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Biodexa Pharmaceuticals | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Biodexa Pharmaceuticals | 6-K：外國發行人報告
美股sec公告 ·  05/15 18:50
牛牛AI助理已提取核心訊息
Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company listed on NASDAQ under the ticker BDRX, has announced the posting of its Annual Report and the Notice of its upcoming Annual General Meeting (AGM). The AGM is scheduled to take place at the company's Cardiff office on June 13, 2024, at 12.00 noon BST. Shareholders have been provided with details on proxy voting in the Notice of AGM. The company, which specializes in developing treatments for diseases with unmet medical needs, has also disclosed its total voting rights, amounting to 2,238,225,722 Ordinary Shares, with no shares held in treasury. Biodexa's lead development programs include eRapa for Familial Adenomatous Polyposis and Non Muscle Invasive Bladder Cancer, tolimidone for type 1 diabetes, and MTX110 for rare/orphan brain cancer indications. The company's proprietary drug delivery technologies aim to enhance the bio-delivery and bio-distribution of medicines. The Annual Report and AGM Notice are available on the Biodexa Pharmaceuticals website.
Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company listed on NASDAQ under the ticker BDRX, has announced the posting of its Annual Report and the Notice of its upcoming Annual General Meeting (AGM). The AGM is scheduled to take place at the company's Cardiff office on June 13, 2024, at 12.00 noon BST. Shareholders have been provided with details on proxy voting in the Notice of AGM. The company, which specializes in developing treatments for diseases with unmet medical needs, has also disclosed its total voting rights, amounting to 2,238,225,722 Ordinary Shares, with no shares held in treasury. Biodexa's lead development programs include eRapa for Familial Adenomatous Polyposis and Non Muscle Invasive Bladder Cancer, tolimidone for type 1 diabetes, and MTX110 for rare/orphan brain cancer indications. The company's proprietary drug delivery technologies aim to enhance the bio-delivery and bio-distribution of medicines. The Annual Report and AGM Notice are available on the Biodexa Pharmaceuticals website.
Biodexa Pharmaceuticals PLC是一家在納斯達克上市的臨床階段生物製藥公司，股票代碼爲BDRX，已宣佈發佈其年度報告和即將舉行的年度股東大會（AGM）的通知。股東周年大會定於英國夏令時間2024年6月13日中午12點在公司的加的夫辦公室舉行。股東周年大會通知中已向股東提供了有關代理投票的詳細信息。該公司專門爲醫療需求未得到滿足的疾病開發治療方法，還披露了其總投票權，總額爲2,238,225,722股普通股，國庫中沒有持有任何股份。Biodexa 的主要開發項目包括用於家族性腺瘤性息肉病和非肌肉浸潤性膀胱癌的 eRapa、用於 1 型糖尿病的託利米酮和用於罕見/孤兒腦癌適應症的 MTX110。該公司專有的藥物遞送技術旨在增強藥物的生物遞送和生物分佈。年度報告和股東周年大會通知可在Biodexa製藥網站上查閱。
Biodexa Pharmaceuticals PLC是一家在納斯達克上市的臨床階段生物製藥公司，股票代碼爲BDRX，已宣佈發佈其年度報告和即將舉行的年度股東大會（AGM）的通知。股東周年大會定於英國夏令時間2024年6月13日中午12點在公司的加的夫辦公室舉行。股東周年大會通知中已向股東提供了有關代理投票的詳細信息。該公司專門爲醫療需求未得到滿足的疾病開發治療方法，還披露了其總投票權，總額爲2,238,225,722股普通股，國庫中沒有持有任何股份。Biodexa 的主要開發項目包括用於家族性腺瘤性息肉病和非肌肉浸潤性膀胱癌的 eRapa、用於 1 型糖尿病的託利米酮和用於罕見/孤兒腦癌適應症的 MTX110。該公司專有的藥物遞送技術旨在增強藥物的生物遞送和生物分佈。年度報告和股東周年大會通知可在Biodexa製藥網站上查閱。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。